News and Updates

iVeena announces the commencement of a 36 patient Phase 1/2a pilot clinical study for the treatment of Keratoconus.

04 February 2019

iVeena announces the commencement of a 36 patient Phase I/2a pilot clinical study for the treatment of Keratoconus (IVMED-80). The Company has Orphan Drug Designation for this product.

Mountain Pacific Venture Fund invests in ocular drug development company iVeena

04 February 2019

iVeena announces the first close for its $2,750M Series B financing by Mountain Pacific Venture Fund, a health care/biotech focused venture fund.

iVeena receives Notice of Allowance from the US Patent Office for patent protecting cataract implants (IVMED 10&20).

12 December 2017

Salt Lake City, Utah,--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a biopharmaceutical company that develops innovative ophthalmology products, today announced that the United States Patent and Trademark Office (USPTO) communicated a notice of allowance for a patent assigned to the University of Utah and licensed to iVeena Delivery Systems Inc.

iVeena Receives FDA Orphan Drug Designation for IVMED-80 for the Treatment of Keratoconus

30 October 2017

iVeena announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IVMED-80, for the treatment of keratoconus. Keratoconus is a degenerative disorder causing a cornea to become conical in shape that can seriously distort vision. This may lead to a corneal transplant. IVMED-80 is the first eye-drop, non-surgical, non-laser treatment for medical crosslinking of the cornea.

iVeena Completes Phase I/2a Pilot Clinical Study of IVMED-10, a Bioerodable, Sustained Release, Intracapsular Implant to Treat Inflammation and Pain Associated with Cataract Surgery

28 October 2017

iVeena Completes Phase 1/2a Pilot Clinical Study for IVMED-10, a Bioerodable, Sustained Release, Intracapsular Implant that Delivers Dexamethasone to Both Anterior and Posterior Eye Segments to Treat Inflammation and Pain Associated with Cataract Surgery.

iVeena has been awarded a total of $450K in NSF and NIH grants to advance its Keratoconus Orphan Drug candidate and Gene Therapy programs.

06 September 2017

"iVeena is pleased to receive a total of $450K in Federal Government grants to advance its portfolio programs," said Gerald Simmons, CEO. "$225K is an NIH grant for its Keratoconus Orphan Drug candidate. IVMED-80 is the first eye-drop, non-surgical, non-laser treatment for medical crosslinking of the cornea. $225K is an NSF grant for iVeena’s Gene Therapy program for various ophthalmic applications.”

iVeena announces the initiation of its Phase I/2b in-human pilot clinical study for IVMED-10, a bioerodable implant designed to eliminate the need for eye drops after cataract surgery.

31 May 2017

On Monday, May 30th, iVeena initiated the Phase I/2a pilot clinical study for IVMED-10. This product is a bioerodable dexamethasone implant given at the time of cataract surgery that releases the drug in the lens capsule over an approximate two week period. “This product is designed to eliminate the need for daily administration of a steroid and an NSAID that published reports show is highly confusing and difficult for a significant portion of the older target population that under go cataract surgery," said Jerry Simmons, CEO. The market for post surgery cataract drops exceeds $1B annually. Results of the study should be available late July or early August, this year.

iVeena to present at the BioTech Showcase Conference that runs in parallel with the JP Morgan Conference in San Francisco on Wednesday, January 11, 2017

10 January 2017

iVeena to present at the BioTech Showcase Conference that runs in parallel with the JP Morgan Conference in San Francisco on Wednesday, January 11, 2017

iVeena has been awarded a $150K 2017 USTAR Technology Acceleration Grant to advance development of IVMED-70, our innovative Glaucoma MIGS (Minimally Invasive Glaucoma Stent) device.

01 December 2016

Glaucoma affects approximately three million individuals in the US and can lead to blindness if not treated. The current standard of care is to administer eye drops on a daily basis that results in a high level of patient non-compliance and the resulting series side effects. The first MIGS device to eliminate the need for eye drops was recently approved. iVeena has developed what we consider is an improved product (increased aqueous outflow) compared to the currently marked products. “The USTAR TAP grant will allow iVeena to accelerate its pre-clinical development of this product and improve our chances of moving forward to clinical studies" said Jerry Simmons, CEO.